• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/10/21 4:15:21 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IVA alert in real time by email
    SC 13G 1 tm216097-1_sc13g.htm SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. __)*

     

    Inventiva S.A.

     

     

    (Name of Issuer)

     

    Ordinary Shares, €0.01 par value per share

     

     

    (Title of Class of Securities)

     

    46124U107

     

     

    (CUSIP Number)

     

    December 31, 2020

     

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    ¨Rule 13d-1(c)

     

    xRule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 46124U107

     

    1.

    Names of Reporting Persons

     

    Frédéric Cren

     

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

     

      (a)   ¨
      (b)   ¨
    3.

    SEC USE ONLY

     

     

    4.

    Citizenship or Place of Organization

     

    France

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

     

    5,612,224 (see Item 4 herein)

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    5,612,224

    8.

    Shared Dispositive Power

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,612,224

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)    ¨

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    14.6%* (See Item 4 herein)

     

    12.

    Type of Reporting Person (see instructions)

     

    IN

     

     

    * Represents the percentage ownership based on 38,393,011 ordinary shares, €0.01 par value per share, of Inventiva S.A. outstanding as of July 15, 2020, as reported in the Current Report on Form 6-K filed on September 16, 2020.

     

     

     

     

    Item 1(a). Name of Issuer: Inventiva S.A.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices: 50 rue de Dijon, 21121 Daix, France
       
    Item 2(a).

    Name of Person Filing:

     

    Frédéric Cren

       
    Item 2(b).

    Address of Principal Business Office or, if none, Residence: The address and principal business office of the Reporting Person is:

     

    c/o Inventiva S.A.

    50 rue de Dijon

    21121 Daix France

       
    Item 2(c).

    Citizenship:

     

    France

     

    Item 2(d).

    Title of Class of Securities:

     

    Ordinary Shares, €0.01 par value per share

     

    Item 2(e).

    CUSIP Number:

     

    46124U107

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
       
    (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
         
    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) ¨ Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);
         
    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ¨ A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
         
    (k) ¨ Group, in accordance with §240.13d–1(b)(1)(ii)(K).
         
      If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____

     

     

     

     

    Item 4.Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

     

    (a)Amount Beneficially Owned:

     

    As of December 31, 2020, Mr. Cren beneficially owned 5,612,224 ordinary shares, €0.01 par value per share (the “Ordinary Shares”), of Inventiva S.A. (the “Issuer”). Under the bylaws of the Issuer, a double voting right is attached to each registered ordinary share which is held in the name of the same shareholder for at least two years. As a result, double voting rights attach to the 5,612,224 Ordinary Shares held by Mr. Cren.

     

    (b)Percent of Class:

     

    Based on 5,612,224 Ordinary Shares, Mr. Cren beneficially owned 14.6% of the Issuer’s outstanding Ordinary Shares, representing 23.4% of the total voting power of the Issuer’s outstanding Ordinary Shares.

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 5,612,224

     

    (ii)Shared power to vote or to direct the vote: 0

     

    (iii)Sole power to dispose or to direct the disposition of: 5,612,224

     

    (iv)Shared power to dispose or to direct the disposition of: 0

     

    Item 5.Ownership of 5 Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

     

    Item 6.Ownership of More than 5 Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of a Group

     

    Not applicable.

     

    Item 10.Certification

     

    Not applicable.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 10, 2021
      Date
       
      /s/ Frédéric Cren
      Frédéric Cren

     

     

     

    Get the next $IVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IVA

    DatePrice TargetRatingAnalyst
    1/28/2026$18.00Overweight
    Barclays
    1/12/2026$12.00Outperform
    Leerink Partners
    1/7/2026$12.00Buy
    UBS
    11/6/2025$13.00Outperform
    Wolfe Research
    9/3/2025$20.00Buy
    H.C. Wainwright
    8/27/2025$26.00Overweight
    Piper Sandler
    2/21/2025$10.00Buy
    TD Cowen
    11/12/2024$3.00Neutral
    UBS
    More analyst ratings

    $IVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

    Daix (France), New York (United States), February 4, 2025 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that CEO Andrew Obenshain has been invited to participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. The conference is being held February 11-12, 2026 at the Lotte New York Palace in New York City. Inventiva leadership will also hold one-on-one meetings during the conference. The fireside chat details are as follows: Date: Wednesday, February 11, 2026Tim

    2/4/26 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

    Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of 31 December 2025: Cash: € 526,751.56Number of shares: 58,515 Number of executions on buy side on semester: 2,332Number of ex

    1/26/26 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference

    Daix (France), New York City (New York, United States), December 17, 2025 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that CEO Andrew Obenshain has been invited to present a corporate overview, and will engage with Inventiva's leadership team in investor meetings, at the upcoming 44th Annual J.P. Morgan Healthcare Conference. The conference is being held on January 12-15, 2026 at the Westin St. Francis in San Francisco, California. Inventiva leadership is also scheduling one-on-one meetings Wedne

    12/17/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    SEC Filings

    View All

    SEC Form 6-K filed by Inventiva S.A.

    6-K - Inventiva S.A. (0001756594) (Filer)

    11/28/25 6:05:04 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Inventiva S.A.

    6-K - Inventiva S.A. (0001756594) (Filer)

    11/21/25 6:54:31 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Inventiva S.A.

    SCHEDULE 13D/A - Inventiva S.A. (0001756594) (Subject)

    11/19/25 8:52:49 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Inventiva with a new price target

    Barclays initiated coverage of Inventiva with a rating of Overweight and set a new price target of $18.00

    1/28/26 7:17:30 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Inventiva with a new price target

    Leerink Partners initiated coverage of Inventiva with a rating of Outperform and set a new price target of $12.00

    1/12/26 8:13:43 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on Inventiva with a new price target

    UBS resumed coverage of Inventiva with a rating of Buy and set a new price target of $12.00

    1/7/26 8:39:16 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Leadership Updates

    Live Leadership Updates

    View All

    Inventiva Appoints Andrew Obenshain as Chief Executive Officer

    Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the appointment of Andrew Obenshain as Chief Executive Officer ("CEO") of the Company. Mr. Obenshain will also join the Company's Board of Directors. He succeeds Frédéric Cren, the Company's co-founder, who has served as CEO since its inception in 2012. Mr. Cren is also stepping down from the Board of Directors and will work with Mr. Obenshain to ensure a smooth tr

    10/1/25 2:30:00 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

    Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MDMartine Zimmermann, PharmD, joins as Executive Vice President of Regulatory Affairs and Quality AssuranceThese key leadership appointments underscore Inventiva's commitment to long-term growth and operational excellence, with topline results from NATiV3 on track for the second half of 2026 Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic

    7/9/25 4:05:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

    Daix (France), New York City (New York, United States), June 10, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the appointment of Renée Aguiar-Lucander to its Board of Directors. The appointment was approved by shareholders at the recent Company's Annual General Meeting. Mark Pruzanski, Chairman of Inventiva: "We are thrilled to welcome Renée to the Board at this pivotal moment in Inventiva's journey. Her exceptional track record in our industry speaks for itself and will be

    6/10/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

    SC 13D/A - Inventiva S.A. (0001756594) (Subject)

    10/21/24 9:00:40 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

    SC 13D/A - Inventiva S.A. (0001756594) (Subject)

    10/21/24 8:54:43 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

    SC 13D/A - Inventiva S.A. (0001756594) (Subject)

    7/19/24 4:30:23 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Financials

    Live finance-specific insights

    View All

    Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

    Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the "Structured Financi

    5/5/25 2:30:00 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva reports its 2024 full year results and provides a business update

    Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50% Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical c

    3/26/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

    Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder

    3/19/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care